Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People with locally advanced or spreading (metastatic) solid tumour cancers that have been confirmed by laboratory testing, where standard treatments have stopped working, are not available, or caused intolerable side effects
• People who have at least one tumour that can be measured using standard imaging criteria (called RECIST 1.1)
• People who are willing to provide a fresh tumour tissue sample
• People with a good general level of physical functioning (rated 0 or 1 on a standard scale used by doctors, meaning fully active or able to carry out light activity)
• People with a life expectancy of at least 12 weeks
• People who agree to use effective contraception throughout the study
• Women who are confirmed to not be pregnant at the start of the study, or who cannot become pregnant
• People who have read, understood, and signed the informed consent form

Who may not be able to join:

• People who have previously received or are currently receiving a treatment that targets a protein called B7-H3
• People who have received certain cancer treatments (chemotherapy, experimental drugs, or anticancer medicines) within 14 days before starting the study drug
• People who have received a monoclonal antibody treatment within 28 days before starting the study drug
• People who have had certain types of radiotherapy (radiation therapy) within 2 to 4 weeks before starting the study drug, depending on the type received
• People who have fluid build-up around the lungs, abdomen, or heart that requires medical treatment
• People who have had major surgery within 4 weeks before starting the study drug
• People who have cancer that has spread to the brain or is pressing on the spinal cord
• People currently taking, or who need to take during the study, certain medicines that affect how the body processes drugs (specific enzyme or drug-transport pathways) or that are known to affect heart rhythm in a potentially dangerous way
• People with mutations in the BRCA or ATM genes
• People who still have significant side effects (above Grade 2 severity) from previous cancer treatments, except for hair loss or nerve-related side effects
• People with a history of another separate primary cancer
• People with poor bone marrow function or significant organ problems
• People with signs of cardiovascular (heart and blood vessel) risk or serious, uncontrolled, or active heart or blood vessel disease
• People with severe or poorly controlled diabetes, including those who have had a serious diabetic episode within the past 6 months, or whose blood sugar control measure (HbA1c) is 7.5% or higher at screening
• People with severe or poorly controlled high blood pressure
• People who have had significant bleeding or a clear tendency to bleed within 1 month before starting the study drug
• People who have had a serious blood clot in an artery or vein within 3 months before starting the study drug
• People who have had a serious infection within 4 weeks before starting the study drug
• People who have been on continuous steroid treatment for more than 30 days within the past 30 days, need long-term steroid treatment, have immune deficiency conditions, or have had an organ transplant
• People with active infections before the first dose, such as hepatitis B, hepatitis C, tuberculosis, syphilis, or HIV
• People with serious liver conditions, including a type of cirrhosis rated Child-Pugh Grade B or worse, hepatic encephalopathy, or hepatorenal syndrome
• People with moderate or severe urinary tract or kidney conditions that could interfere with detecting or treating drug-related urinary side effects
• People with a history of serious nerve or mental health disorders
• Women who are breastfeeding, pregnant, or planning to become pregnant during the study
• People who have received a vaccine or experienced any allergic reaction within 4 weeks before starting the study drug
• People with a history of severe allergic reactions to infused treatments or to proteins derived from human or mouse sources
• People who are allergic to any ingredient in the study drug (HS-20093)
• People who, in the trial doctor's opinion, are unlikely to follow the study requirements
• People with any other condition that, in the trial doctor's opinion, could affect their safety or the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.